Newsroom
Subscribe
Contact
About us
About us
Company Overview
Team
Careers
Our Science
Our Science
Pipeline
Pipeline
Investors
Investors
Investor Overview
Press Releases
Events + Presentations
Company Information
SEC Filings
Stock Information
Corporate Governance
News Alerts
Press Releases
Overview
Press Releases
Events+Presentations
Company info
Stock Information
SEC Filings
Corp. governance
News Alerts
Recent Press Releases
October 3, 2023
Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates
September 27, 2023
Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry
September 20, 2023
Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates
September 18, 2023
Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023
September 11, 2023
Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives
September 5, 2023
Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives
View All
